Cisplatin and Carboplatin Resistance in Ovarian Cancer
Author Information
Author(s): M.E. Gore, I. Fryatt, E. Wiltshaw, T. Dawson, B.A. Robinson, A.H. Calvert
Primary Institution: Royal Marsden Hospital
Hypothesis
Is there clinical evidence for non-cross-resistance between cisplatin and carboplatin in ovarian cancer?
Conclusion
The study found that while some patients responded to the second platinum treatment, there was no significant survival advantage compared to non-responders.
Supporting Evidence
- Three patients (6.5%) responded to the second treatment.
- Patients who responded had no survival advantage compared to non-responders.
- The overall response rate after switching treatments was low.
Takeaway
Doctors tried switching cancer patients from one type of medicine to another to see if it would help, but only a few got better.
Methodology
Patients with resistant ovarian cancer were treated with either cisplatin or carboplatin and then switched to the other drug.
Limitations
The number of responders was very small, making the findings likely not clinically valuable.
Participant Demographics
Patients had histologically confirmed epithelial ovarian cancer.
Statistical Information
P-Value
0.4
Statistical Significance
p=0.4
Want to read the original?
Access the complete publication on the publisher's website